The Latest Insight on Anti-Aging Therapeutics Targeting Cardiovascular Disease

According to French scientists, no organ system appears as vulnerable to aging as the cardiovascular system, and anti-aging therapeutics may help mitigate the effects of cardiovascular disease.

(The principal investigator behind the review, aging researcher Guido Kroemer | Olympiad in Cardiovascular Medicine)

Anti-aging therapeutics may prevent and slow age-related cardiovascular dysfunction.

Cardiovascular

Participants: Healthy middle-aged adults (average age: 55)
Dosage: 100 mg/day of Monarda didyma L. extract, preferably at lunchtime with plenty of water, for 12 weeks

An extract made from Monarda didyma L. reduces the biological age of older adults while improving their quality of life. 

A flower from the Monarda didyma L. plant (image: nativeplanttrust.org) 

Clinical Trials

Model: Ten-month-old male EFAD mice 
Dosage: 14.4 ppm of alfatradiol in diet for five months

USC Study: Longevity-Promoting Drug Counteracts a Genetic Predisposition to Alzheimer's

The drug alfatradiol, also known as 17ɑ-estradiol, reduces cognitive errors on a test of memory and lowers neuronal plaques in mice genetically predisposed to Alzheimer’s disease.

(The University of Southern California | College Matchpoint)

Researchers unveil data suggesting the drug alfatradiol improves signs of frailty, reduces cognitive errors, and reduces neuronal plaques in mice with a genetic predisposition to Alzheimer’s disease.

Brain &amp; Neurons

Model: UM-HET3 mice and 5XFAD mice 
Dosage: UM=HET3 mice received 180 mg/kg canagliflozin in chow starting at seven months of age, and FXFAD mice received 180 mg/kg canagliflozin in chow beginning at three months of age

New Study: Diabetes Medication Improves Cognition and Alleviates Alzheimer’s Progression

The diabetes drug canagliflozin improves learning and memory in middle-aged male mice and reduces brain plaques in Alzheimer’s model mice.

The FDA-approved diabetes medication canagliflozin improves cognition in a mouse model of Alzheimer’s disease in males only.

Model: C3B6F1 hybrid mice 
Dosage: 42 mg/kg of rapamycin and 1.44 mg/kg of trametinib in food starting at 6 months of age

Latest Research: Two FDA-Approved Drugs Additively Extend Lifespan

Researchers at the Max Planck Institute have unveiled that combining trametinib with rapamycin, drugs used in cancer treatment, extends average lifespan by 29% in female mice and 27% in male mice, respectively.

(The study’s lead author, Linda Partridge | The Biologist)

Combining two cancer treatment drugs, trametinib and rapamycin, extends lifespan by 29% and 27% in middle-aged female and male mice, respectively.

Search Result: middle-age

The Latest Insight on Anti-Aging Therapeutics Targeting Cardiovascular Disease

Flower Extract Slows Cellular Aging & Improves Life Quality, New Study Shows

USC Study Suggests Longevity-Promoting Drug Counteracts a Genetic Predisposition to Alzheimer’s

Diabetes Medication Improves Cognition and Alleviates Alzheimer’s Progression, Suggests New Study

Latest Research: Two FDA-Approved Drugs Additively Extend Lifespan